KR102938141B1 - Tyk2 슈도키나제 리간드 - Google Patents

Tyk2 슈도키나제 리간드

Info

Publication number
KR102938141B1
KR102938141B1 KR1020227018394A KR20227018394A KR102938141B1 KR 102938141 B1 KR102938141 B1 KR 102938141B1 KR 1020227018394 A KR1020227018394 A KR 1020227018394A KR 20227018394 A KR20227018394 A KR 20227018394A KR 102938141 B1 KR102938141 B1 KR 102938141B1
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227018394A
Other languages
English (en)
Korean (ko)
Other versions
KR20220107194A (ko
Inventor
라주 모한
존 누쓰
제이슨 해리스
센동 유안
Original Assignee
벤틱스 바이오사이언스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 벤틱스 바이오사이언스, 인크. filed Critical 벤틱스 바이오사이언스, 인크.
Publication of KR20220107194A publication Critical patent/KR20220107194A/ko
Application granted granted Critical
Publication of KR102938141B1 publication Critical patent/KR102938141B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227018394A 2019-11-08 2020-11-05 Tyk2 슈도키나제 리간드 Active KR102938141B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962933179P 2019-11-08 2019-11-08
US62/933,179 2019-11-08
US202063046514P 2020-06-30 2020-06-30
US63/046,514 2020-06-30
PCT/US2020/059210 WO2021092246A1 (en) 2019-11-08 2020-11-05 Tyk2 pseudokinase ligands

Publications (2)

Publication Number Publication Date
KR20220107194A KR20220107194A (ko) 2022-08-02
KR102938141B1 true KR102938141B1 (ko) 2026-03-11

Family

ID=75846491

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018394A Active KR102938141B1 (ko) 2019-11-08 2020-11-05 Tyk2 슈도키나제 리간드

Country Status (17)

Country Link
US (2) US11753411B2 (https=)
EP (1) EP4054581A4 (https=)
JP (1) JP7635228B2 (https=)
KR (1) KR102938141B1 (https=)
CN (1) CN114929226B (https=)
AU (1) AU2020378345A1 (https=)
BR (1) BR112022008821A2 (https=)
CA (1) CA3160637A1 (https=)
CL (1) CL2022001178A1 (https=)
CO (1) CO2022007814A2 (https=)
GE (1) GEP20257840B (https=)
IL (1) IL292785B2 (https=)
MX (1) MX2022005563A (https=)
PH (1) PH12022551105A1 (https=)
TW (1) TWI882032B (https=)
UA (1) UA129894C2 (https=)
WO (1) WO2021092246A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019364336B2 (en) 2018-10-22 2023-11-16 Alumis Inc. TYK2 inhibitors and uses thereof
US20220135567A1 (en) * 2019-02-07 2022-05-05 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
CA3132632A1 (en) * 2019-03-11 2020-09-17 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
AU2020247990A1 (en) 2019-03-26 2021-11-11 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
KR102938141B1 (ko) 2019-11-08 2026-03-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나제 리간드
KR20220140515A (ko) 2020-01-13 2022-10-18 버지 애널리틱스, 인크. 치환된 피라졸로-피리미딘 및 그의 용도
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用
US20240010654A1 (en) * 2022-07-06 2024-01-11 Ventyx Biosciences, Inc. Crystalline forms of a tyk2 inhibitor
CN120897919A (zh) * 2023-01-13 2025-11-04 温缇克斯生物科学公司 Tyk2抑制剂的制备
CN117247389A (zh) * 2023-09-18 2023-12-19 南京友怡医药科技有限公司 一种靶向药物化合物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519226A (ja) 2003-02-28 2006-08-24 帝人ファーマ株式会社 ピラゾロ［１，５−ａ］ピリミジン誘導体
JP2009511486A (ja) 2005-10-06 2009-03-19 シェーリング コーポレイション プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法
US20120114739A1 (en) 2009-04-09 2012-05-10 Yongqi Deng PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
JP2018532760A (ja) 2015-11-06 2018-11-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ−ガンマ阻害薬としての複素環式化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
MA46620A (fr) 2016-10-28 2021-05-26 Bristol Myers Squibb Co Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha
JP7160824B2 (ja) 2017-03-08 2022-10-25 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤、使用およびその製造のための方法
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
SG11201910197SA (en) 2017-05-15 2019-11-28 Dana Farber Cancer Inst Inc Compounds for treating dengue virus infection and other viral infections
KR102717819B1 (ko) 2017-07-28 2024-10-14 다케다 야쿠힌 고교 가부시키가이샤 Tyk2 억제제 및 이의 용도
JP7179161B2 (ja) 2018-09-10 2022-11-28 イーライ リリー アンド カンパニー 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体
JP7619951B2 (ja) 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
TWI800696B (zh) 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
US20220135567A1 (en) 2019-02-07 2022-05-05 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
CA3132632A1 (en) 2019-03-11 2020-09-17 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
AU2020247990A1 (en) 2019-03-26 2021-11-11 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
KR102938141B1 (ko) 2019-11-08 2026-03-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나제 리간드

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519226A (ja) 2003-02-28 2006-08-24 帝人ファーマ株式会社 ピラゾロ［１，５−ａ］ピリミジン誘導体
JP2009511486A (ja) 2005-10-06 2009-03-19 シェーリング コーポレイション プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法
US20120114739A1 (en) 2009-04-09 2012-05-10 Yongqi Deng PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
JP2018532760A (ja) 2015-11-06 2018-11-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ−ガンマ阻害薬としての複素環式化合物

Also Published As

Publication number Publication date
EP4054581A1 (en) 2022-09-14
JP2022553841A (ja) 2022-12-26
BR112022008821A2 (pt) 2022-08-23
WO2021092246A1 (en) 2021-05-14
TWI882032B (zh) 2025-05-01
IL292785A (en) 2022-07-01
AU2020378345A1 (en) 2022-06-02
US20210139486A1 (en) 2021-05-13
EP4054581A4 (en) 2023-11-22
CO2022007814A2 (es) 2022-09-09
CA3160637A1 (en) 2021-05-14
CN114929226A (zh) 2022-08-19
KR20220107194A (ko) 2022-08-02
TW202128698A (zh) 2021-08-01
IL292785B1 (en) 2025-05-01
PH12022551105A1 (en) 2023-11-20
UA129894C2 (uk) 2025-09-03
IL292785B2 (en) 2025-09-01
US11753411B2 (en) 2023-09-12
US20230348478A1 (en) 2023-11-02
GEP20257840B (en) 2025-12-25
MX2022005563A (es) 2022-08-19
JP7635228B2 (ja) 2025-02-25
CN114929226B (zh) 2024-09-27
CL2022001178A1 (es) 2023-02-03

Similar Documents

Publication Publication Date Title
KR102938141B1 (ko) Tyk2 슈도키나제 리간드
US11780842B2 (en) TYK2 pseudokinase ligands
KR20210124409A (ko) Tyk2 슈도키나제 리간드
KR102916168B1 (ko) Jak 억제제
JP2022549435A (ja) Ｊａｋ阻害剤
EP4009967A1 (en) Jak inhibitors
HK40080028B (zh) Tyk2假激酶配体
EA047570B1 (ru) Лиганды псевдокиназы tyk2
HK40080028A (en) Tyk2 pseudokinase ligands

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)